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This report describes the total and facile synthesis of 30-C-cyano & 30-C-cyano-30-deoxy pyrimidine
pyranonucleosides. Reaction of 3-keto glucoside 1 with sodium cyanide gave the desired precursor
3-C-cyano-1,2:5,6-di-O-isopropylidene-a-D-glucofuranose (2). Hydrolysis followed by acetylation led
to the 1,2,3,4,6-penta-O-acetyl-3-C-cyano-D-glucopyranose (4). Compound 4 was condensed with
silylated 5-fluorouracil, uracil, thymine and N4-benzoylcytosine, respectively and deacetylated to
afford the target 1-(30-C-cyano-b-D-glucopyranosyl)nucleosides 6aed. Routine deoxygenation at
position 30 of cyanohydrin 2, followed by hydrolysis and acetylation led to the 3-C-cyano-3-deoxy-
1,2,4,6-tetra-O-acetyl-D-allopyranose (10). Coupling of sugar 10 with silylated pyrimidines and
subsequent deacetylation yielded the target 1-(30-C-cyano-30-deoxy-b-D-allopyranosyl)nucleosides
12aed. The new analogues were evaluated for their antiviral and cytostatic activities. It was found that
6a was endowed with a pronounced anti-proliferative activity that was only 2- to 8-fold less potent
than that shown for the parental base 5-fluorouracil. None of the compounds showed activity against
a broad panel of DNA and RNA viruses.
 2011 Elsevier Masson SAS. All rights reserved.1. Introduction
Modified nucleosides constitute a major class of biologically
active compounds, especially as antitumor and antiviral agents
[1e4]. Cytotoxic nucleoside analogues were among the first
chemotherapeutic agents to be introduced for the medical treat-
ment of cancer [5]. Nucleoside chemistry has also evolved to
facilitate efficient routes to effective agents for the treatment of
viral diseases caused by HIV [6] and herpes viruses [7]. Subse-
quently, nucleosides, which are frequently altered in the carbohy-
drate or base moiety, became the focus for the development of
novel chemotherapeutic agents.
During the last decades, several branched-chain sugar nucleo-
sides have been extensively studied for their potential antitumor or
antiviral properties [8e11]. Attachment of the cyano group to the
sugar moiety has been an attractive object for nucleoside chemists
due to its small size and its great electron withdrawing character.
Thus, cyano ribofuranose nucleosides have been reported as
interesting antiviral agents [12e14], while replacement of the
hydroxyl group of 1-b-D-arabinofuranosylcytosine (ara-C) by the: þ30 2410 565290.
son SAS. All rights reserved.cyano group led to a newbiologically active compound [15,16], with
a novel mechanism of anticancer action [17].
Lately, nucleosides bearing pyranosyl rings have been evaluated
for their potential antiviral [18e20], antioxidant [21] and antibiotic
[22] properties and as building blocks in nucleic acid synthesis
[23,24]. As part of our efforts to develop novel biologically active
agents, we recently reported that new classes of uncommon 30-fluo-
rinated pyranonucleosides have a promising potential in combating
the rotaviral infections and in the treatment of colon cancer, and are
efficient as antitumor growth inhibitors [25e29]. Experimental data
also revealed that human poly(A)-specific ribonuclease [30] and
glycogenphosphorylase [31]areamongthemolecular targetsof these
compounds.
In view of the interesting biological activity of the fluorinated
pyranonucleosides, we decided to extend our studies to the
synthesis of novel molecules in which an electron withdrawing
cyano group replaces the fluorine atom. Therefore, we report the
stereocontrolled synthesis of novel branched-chain C-cyano pyrim-
idine pyranonucleosides, i.e. 30-C-cyano-b-D-glucopyranonucleo-
sides and 30-C-cyano-30-deoxy-b-D-allopyranonucleosides, bearing
5-fluorouracil, uracil, thymine and cytosine as heterocyclic bases,
in order to assess their biological activity. The chemical synthesis and
biological activity of these compounds are presented herein.
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2.1. Chemistry
30-C-Cyano-b-D-glucopyranonucleosides 6aed were prepared
according to the synthetic route outlined in Scheme 1. Treatment
of the 1,2:5,6-di-O-isopropylidene-a-D-ribo-hexofuranos-3-ulose
(1) [32] with sodium cyanide in a two-phase ethylether/H2O
system, in the presence of sodium bicarbonate, afforded the
thermodynamically more stable gluco cyanohydrin epimer 2, in
a virtually quantitative yield [33,34]. The assignment of its
configuration was further supported by NOE measurements, as
depicted in Fig. 1. A 5% NOE enhancement of H-2 and a 7% NOE
enhancement of H-5 on irradiation of the proton of the free OH
group show that these protons are on the same side of the ring
system. Hydrolysis of 2 using Amberlite IR 120 (Hþ) resin in
methanol followed by acetylation using acetic anhydride (Ac2O) in
pyridine [32] led to the 1,2,3,4,6-penta-O-acetyl-3-C-cyano-D-
glucopyranose (4). The protected, 1-(20,30,40,60-tetra-O-acetyl-30-C-
cyano-b-D-glucopyranosyl) pyrimidine nucleosides 5aed were
obtained upon coupling of the precursor material 4 with silylated
5-fluorouracil, uracil, thymine and N4-benzoylcytosine, respec-
tively, in the presence of trimethylsilyl trifluomethane-sulfonate
(Me3SiOSO2CF3), in refluxing acetonitrile [35]. The 1H NMR
spectra obtained for the protected nucleosides 5aed, showed large
coupling constants between protons H-10 and H-20 (J10,20 ¼
9.4e9.6 Hz), indicating an axial orientation of both protons and
equatorially oriented base rings. Fully deprotection of 5aed, per-
formed by saturated methanolic ammonia [36], gave the desired
nucleosides 6aed.
Compound 2 was the starting material for the synthesis of 30-C-
cyano-b-D-allopyranonucleosides 12aed (Scheme 1). Phenox-
ythiocarbonylation of 2 under a commonly used condition, phenyl
chlorothionoformate, 4-(dimethylamino)pyridine (DMAP) and
triethylamine (Et3N) in CH3CN [16], afforded the 30-O-phenox-
ythiocarbonyl derivative 7, which proved to be unstable during the
purification process. Therefore, crude 7 was directly submitted to
deoxygenation with Bu3SnH in the presence of 2,20-azobis(isobu-
tyronitrile) (AIBN), to give the 30-deoxy derivative sugar 8, in 76%
overall yield. In order to elucidate the structure of the newly
synthesized 8, NOE measurements were performed, as depicted in
Fig. 1. The mutual NOE enhancements observed between H-2 with
both H-1 and H-3 show that all these protons are in the same b face
of the furanose ring. In this type of radical deoxygenation, the
hydrogen atom enters from the less hindered, b-face of the planar
radical intermediate, opposite to the bulky 1,2-O-isopropylidene
group.
Hydrolysis of 8 using Amberlite IR 120 (Hþ) resin in methanol
followed by direct standard acetylation led to the 1,2,4,6-tetra-O-
acetyl-3-C-cyano-3-deoxy-D-allopyranose (10). Condensation of
cyano sugar 10 with per-O-silylated 5-fluorouracil, uracil, thymine
and N4-benzoylcytosine using Me3SiOSO2CF3 as activator, afforded
the 1-(20,40,60-tri-O-acetyl-30-C-cyano-30-deoxy-b-D-allopyranosyl)
pyrimidine nucleosides 11aed, respectively [35]. 1H NMR data
obtained for the newly synthesized nucleosides 11aed (J10,20 ¼
9.4e9.7 Hz, J20 ,30 ¼ 5.0e5.2 Hz), revealed the b-configuration of the
sugar moiety and an axial oriented cyano group, respectively.
Finally, treatment of 11aed with hydrazine hydrate in buffered
acetic acid (AcOH)epyridine gave the fully deprotected nucleosides
12aed, in yields that varied from 55% to 75%. Interestingly,
attempts to deprotect 11aed by NH3/methanol (MeOH) under the
subsequent basic conditions produced complex mixtures, con-
taining b-elimination products, probably due to the acidity of H-30
and the presence of two leaving groups (OAc) at the 20- and 40-
positions of the sugar moiety.2.2. Biological activity
The cytostatic activityof6aed and12aedwasdetermined against
murine leukemia L1210, human lymphocyte CEM and human cervix
carcinomaHeLacell cultures. The test compounds showedpoor, if any
cytostatic activity against the three cell lines, except the 30-C-cyano-
5-fluorouracil pyranonucleoside 6a that showed pronounced anti-
proliferative activity against all three cell lines. Its cytostatic activity
spectrum was similar to that of the parent base 5-fluorouracil. It is
currently unclear whether 6a is biologically active as such, or, alter-
natively, acts as a prodrug of 5-fluorouracil, fromwhich the free base
may be released by the action of phosphorolytic enzymes and/or by
a spontaneous release (Table 1).
None of the compounds was endowed with activity against
a broad panel of DNA and RNA viruses in cell culture at 100 mM.
3. Conclusion
In conclusion, the stereocontrolled synthesis of the 30-C-cyano
& 30-C-cyano-30-deoxy pyranonucleoside analogues bearing
5-fluorouracil, uracil, thymine and cytosine, respectively was
undertaken. The target nucleosides were tested for their inhibitory
effects on the proliferation of murine leukemia L1210, human
lymphocyte CEM and human cervix carcinoma HeLa cell cultures.
30-C-Cyano-5-fluorouracil pyranonucleoside 6a showed a similar
cytostatic activity spectrum as the free base 5-fluorouracil.
4. Experimental part
4.1. Chemistry
Melting points were recorded in a Mel-Temp apparatus and are
uncorrected. Thin layer chromatography (TLC) was performed on
Merck precoated 60F254 plates. Reactions were monitored by TLC
on silica gel, with detection by UV light (254 nm) or by charring
with sulfuric acid. Flash column chromatography was performed
using silica gel (240e400 mesh, Merck). 1H and 13C NMR spectra
were obtained at room temperature with a Bruker 400 spectrom-
eter at 400 and 100 MHz, respectively, using CDCl3 and methanol-
d4 (CD3OD) with internal tetramethylsilane (TMS).
UVeVis spectra were recorded on a PG T70 UVeVIS spectrom-
eter and mass spectra were obtained with a Micromass Platform LC
(ESI-MS). Optical rotations were measured using an Autopol I
polarimeter. Infrared spectra were obtained with a Thermo Scien-
tific Nicolet IR100 FT-IR spectrometer. Acetonitrile and toluene
were distilled from calcium hydride and stored over 3E molecular
sieves.
4.2. Synthesis of 1,2,3,4,6-penta-O-acetyl-3-C-cyano-D-
glucopyranose (4)
4.2.1. Synthesis of 3-C-cyano-1,2:5,6-di-O-isopropylidene-a-D-
glucofuranose (2)
A mixture of 1,2:5,6-di-O-isopropylidene-a-D-ribo-hexofur-
anos-3-ulose (1) (4 g, 15.5 mmol), H2O (62 mL), ethylether
(124 mL), sodium bicarbonate (2.6 g, 15.5 mmol) and sodium
cyanide (0.76 g, 7.75 mmol) was stirred vigorously at room
temperature overnight. The organic phase was separated, and the
aqueous phase was washed with ethylether (2 x 124 mL). The
combined ether phases were dried over Na2SO4, filtered and
evaporated to dryness. The residue was purified by flash chro-
matography [(ethylacetate) EtOAc/hexane, 3:7)] to give compound
2 (4.28 g, 97%, Rf ¼ 0.40 in EtOAc/hexane, 3:7) as a white solid, mp
98e100 C [34]. ½a22D þ 46 (c 0.3, CHCl3); 1H NMR (CDCl3): d 5.97 (d,
1H, J1,2 ¼ 3.4 Hz, H-1), 4.59 (d, 1H, H-2), 4.36e4.32 (m, 1H, H-5),
Scheme 1. (i) H2O, ethylether, NaHCO3, NaCN; (ii) H2O, MeOH, Amberlite IR 120 (Hþ); (iii) Ac2O, pyridine; (iv) Silylated base, CH3CN, Me3SiOSO2CF3; (v) Methanolic ammonia; (vi)
Phenyl chlorothionoformate, Et3N, DMAP, CH3CN, 0 C; (vii) Bu3SnH, AIBN, toluene, 100 C; (viii) N2H4$H2O, AcOH, pyridine.
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3eOH), 1.58, 1.55, 1.39, 1.37 (4s, 12H, 4CH3); Anal. Calcd for
C13H19NO6: C, 54.73; H, 6.71; N, 4.91. Found: C, 54.84; H, 6.77; N,
4.82; ESI-MS (m/z): 286.32 (M þ Hþ).4.2.2. Synthesis of 3-C-cyano-D-glucopyranose (3)
To a solution of 2 (2 g, 7.01 mmol) in MeOH (10.9 mL) and H2O
(62.2 mL) was added Amberlite IR 120 (Hþ) resin and the mixture
was refluxed overnight. The reaction mixture was filtered and
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Fig. 1. NOE enhancements measured on compounds 2 and 8.
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EtOAc/MeOH, 9:1) as a viscous oil, and it was used without further
purification. ½a22D  25 (c 0.44, MeOH); Anal. Calcd for C7H11NO6: C,
40.98; H, 5.40; N, 6.83. Found: C, 40.81; H, 5.35, N, 6.92; ESI-MS: (m/
z) 206.19 (M þ Hþ).
4.2.3. Synthesis of 1,2,3,4,6-penta-O-acetyl-3-C-cyano-D-
glucopyranose (4)
Compound 3 (1.25 g, 6.09 mmol) was dissolved in a mixture of
pyridine (21.2 mL) and Ac2O (10.9 mL). The reactionwas carried out
at room temperature for 1 h, thenwas quenched with MeOH at 0 C
and was concentrated in vacuum. The residue was diluted with
EtOAc, washed with saturated sodium bisulfate, sodium bicar-
bonate and H2O. The organic extract was dried over anhydrous
sodium sulfate, filtered and evaporated to dryness to give
compound 4 (2.28 g, 90%, Rf ¼ 0.43 in EtOAc/hexane, 3:7) as
a colorless oil. ½a22D þ 30 (c 1.30, CHCl3); Anal. Calcd for C17H21NO11:
C, 49.16; H, 5.10; N, 3.37. Found: C, 49.40; H, 5.12; N, 3.46; ESI-MS:
(m/z) 416.36 (M þ Hþ).
4.3. Synthesis of 30-C-cyano-b-D-glucopyranonucleosides 6aed
4.3.1. Synthesis of 1-(20,30,40,60-tetra-O-acetyl-30-C-cyano-b-D-
glucopyranosyl)5-fluorouracil (5a)
A mixture of 5-fluorouracil (109 mg, 0.84 mmol), hexamethyldi-
silazane (HMDS) (220 mL, 1.04 mmol) and saccharine (7 mg,
0.039 mmol) in anhydrous CH3CN (3.5 mL) was refluxed for 30 min
under nitrogen. 1,2,3,4,6-Penta-O-acetyl-3-C-cyano-D-glucopyranose
(4) (0.25 g, 0.6 mmol) and Me3SiOSO2CF3 (152 mL, 0.84 mmol) were
then added and the reaction mixture was refluxed for 4 h, cooled,
neutralized with aqueous sodium bicarbonate, and extracted with
CH2Cl2 (200 mL). The organic extract was dried over anhydrous
sodium sulfate, filtered and evaporated to dryness. The residue was
purified by flash chromatography (EtOAc/hexane, 4:6) to give pure 5aTable 1
Cytostatic activity of 6aed and 12aed against a panel of tumor cell lines.
Compound IC50a (mM)
L1210 CEM HeLa
6a 1.9  0.0 32  9.6 4.5  1.2
6b 417  376 > 500 > 500
6c 539  85 > 500 > 500
6d 147  14 > 500 377  0
12a 550  10 > 500 819  44
12b > 500 > 500 811  40
12c > 750 > 750 > 750
12d > 750 > 750 > 750
F-Uracil 0.49  0.13 18  5 0.54  0.12
a 50% inhibitory concentration, or compound concentration required to inhibit
cell proliferation by 50%. Data are the mean of 2e3 independent experiments
(S.D.).(0.18 g, 60%, Rf ¼ 0.47 in EtOAc/hexane, 1:1) as a white solid, mp
114116 C. ½a22D  2 (c 0.37, CHCl3); lmax 262 nm (ε 7950); 1H NMR
(CDCl3): d 8.36 (br s,1H, NH), 7.37 (d,1H, J6,F5¼ 5.6 Hz, H-6), 6.05 (dd,
1H, J10,20 ¼ 9.5 Hz, J10,F5 ¼ 1.2 Hz, H-10), 5.70 (d, 1H, H-20), 5.64 (d, 1H,
J40 ,50 ¼10.2Hz, H-40), 4.45e4.39 (m,1H,H-50), 4.22e4.14 (m, 2H,H-6a0,
H-6b0), 2.16, 2.14, 2.11, 2.04 (4s, 12H, 4OAc); . Anal. Calcd for
C19H20FN3O11: C, 47.02; H, 4.15; N, 8.66; Found: C, 47.22; H, 4.21; N,
8.79. ESI-MS (m/z) 486.39 (M þ Hþ).
4.3.2. Synthesis of 1-(30-C-cyano-b-D-glucopyranosyl)5-
fluorouracil (6a)
Compound 5a (0.18 g, 0.37 mmol) was treated with ammonia/
MeOH (saturated at 0 C, 20.6 mL). The solution was stirred over-
night at room temperature and then was concentrated under
reduced pressure. The residue was purified by flash chromatog-
raphy (CH2Cl2/MeOH, 9:1) to afford pure 6a (76 mg, 65%, Rf ¼ 0.40
in CH2Cl2/MeOH, 8:2) as a white foam. ½a22D þ 20 (c 0.50, CD3OD);
lmax 266 nm (ε 7739); 1H NMR (CD3OD): d 7.95 (d, 1H, J6,F5¼ 6.7 Hz,
H-6), 6.01 (dd,1H, J10,20 ¼ 10.3 Hz, J10,F5¼1.3 Hz, H-10), 3.94e3.67 (m,
5H, H-20, H-40, H-50, H-6a0, H-6b0); 13C NMR (CD3OD): d 159.22,
151.38, 139.15, 127.52, 119.28, 88.32, 79.01, 71.93, 71.70, 68.18, 61.37;
IR (Nujol, cm1): 2230 (CN); Anal. Calcd for C11H12FN3O7: C, 41.65;
H, 3.81; N, 13.25. Found: C, 41.94; H, 3.71; N, 13.51; ESI-MS (m/z)
318.20 (M þ Hþ).
4.3.3. Synthesis of 1-(20,30,40,60-tetra-O-acetyl-30-C-cyano-b-D-
glucopyranosyl)uracil (5b)
Uracil derivative 5b was synthesized from 4 by the similar
procedure as described for 5a. It was purified by flash chromatog-
raphy (EtOAc/hexane, 4:6) to give pure 5b (0.17 g, 61%, Rf ¼ 0.29 in
EtOAc/hexane, 1:1) as a white solid, mp 190192 C. ½a22D  7 (c 0.7,
CHCl3); lmax 260 nm (ε 5777); 1H NMR (CDCl3): d 8.34 (br s,1H, NH),
7.33 (d, 1H, J5,6 ¼ 8.1 Hz, H-6), 6.09 (d, 1H, J10,20 ¼ 9.5 Hz, H-10), 5.85
(d, 1H, H-5), 5.79 (d, 1H, H-20), 5.68 (d, 1H, J40 ,50 ¼ 10.2 Hz, H-40),
4.46e4.42 (m, 1H, H-50), 4.22e4.17 (m, 2H, H-6a0, H-6b0), 2.19, 2.14,
2.12, 2.07 (4s, 12H, 4OAc); Anal. Calcd for C19H21N3O11: C, 48.83; H,
4.53; N, 8.99. Found: C, 48.65; H, 4.11; N, 8.79; ESI-MS (m/z) 468.40
(M þ Hþ).
4.3.4. Synthesis of 1-(30-C-cyano-b-D-glucopyranosyl)uracil (6b)
Uracil derivative 6b was synthesized from 5b by the similar
procedure as described for 6a. The residue was purified by flash
chromatography (CH2Cl2/MeOH, 9:1) to afford pure 6b (70mg, 64%,
Rf ¼ 0.29 in CH2Cl2/MeOH, 8:2) as a white foam. ½a22D þ 7 (c 0.32,
CD3OD); lmax 258 nm (ε 11306); 1H NMR (CD3OD): d 7.70 (d, 1H,
J5,6 ¼ 8.0 Hz, H-6), 6.01 (d, 1H, J10,20 ¼ 9.0 Hz, H-10), 5.70 (d, 1H, H-5),
3.97e3.54 (m, 5H, H-20, H-40, H-50, H-6a0, H-6b0); 13C NMR (CD3OD):
d 164.12, 150.23, 141.44, 119.01, 102.6, 92.22, 79.68, 72.12, 70.9,
68.35, 61.32; IR (Nujol, cm1): 2240 (CN); Anal. Calcd for
C11H13N3O7: C, 44.15; H, 4.38; N, 14.04. Found: C, 43.90; H, 4.28; N,
13.96; ESI-MS (m/z) 300.22 (M þ Hþ).
4.3.5. Synthesis of 1-(20,30,40,60-tetra-O-acetyl-30-C-cyano-b-D-
glucopyranosyl)thymine (5c)
Thymine derivative 5c was synthesized from 4 by the similar
procedure as described for 5a. It was purified by flash chromatog-
raphy (EtOAc/hexane, 4:6) to give pure 5c (0.16 g, 57%, Rf ¼ 0.34 in
EtOAc/hexane, 1:1) as a white solid, mp 127129 C. ½a22D  4 (c
0.39, CHCl3); lmax 259 nm (ε 9402); 1H NMR (CDCl3): d 8.34 (br s,
1H, NH), 7.01 (s, 1H, H-6), 6.08 (d, 1H, J10,20 ¼ 9.6 Hz, H-10), 5.80 (d,
1H, H-20), 5.67 (d, 1H, J40 ,50 ¼ 10.2 Hz, H-40), 4.47e4.38 (m, 1H, H-50),
4.23e4.13 (m, 2H, H-6a0, H-6b0), 2.18, 2.14, 2.12, 2.07 (4s,12H, 4OAc),
1.97 (s, 3H, CH3); Anal. Calcd for C20H23N3O11: C, 49.90; H, 4.82; N,
8.73. Found: C, 49.62; H, 4.58; N, 8.71; ESI-MS (m/z) 482.42
(M þ Hþ).
C. Kiritsis et al. / European Journal of Medicinal Chemistry 46 (2011) 5668e567456724.3.6. Synthesis of 1-(30-C-cyano-b-D-glucopyranosyl)thymine (6c)
Thymine derivative 6c was synthesized from 5c by the similar
procedure as described for 6a. The residue was purified by flash
chromatography (CH2Cl2/MeOH, 9:1) to afford pure 6c (114 mg,
71%, Rf ¼ 0.32 in CH2Cl2/MeOH, 8:2) as a white foam. ½a22D þ 4 (c
0.31, CD3OD); lmax 261 nm (ε 4238); 1H NMR (CD3OD): d 7.57 (s, 1H,
H-6), 6.03 (d, 1H, J10,20 ¼ 9.0 Hz, H-10), 4.00e3.67 (m, 5H, H-20, H-40,
H-50, H-6a0, H-6b0), 1.91 (s, 3H, CH3); 13C NMR (CD3OD): d 162.62,
150.49, 137.12, 119.91,110.69, 92.76, 79.83, 71.01, 70.90, 69.81, 62.46,
13.33; IR (Nujol, cm1): 2245 (CN); Anal. Calcd for C12H15N3O7: C,
46.01; H, 4.83; N, 13.41. Found: C, 45.79; H, 4.61; N, 13.26; ESI-MS
(m/z) 314.28 (M þ Hþ).
4.3.7. Synthesis of 1-(20,30,40,60-tetra-O-acetyl-30-C-cyano-b-D-
glucopyranosyl)N4-benzoylcytosine (5d)
N4-benzoyl cytosine derivative 5d was synthesized from 4 by
the similar procedure as described for 5a. It was purified by flash
chromatography (EtOAc/hexane, 4:6) to give pure 5d (0.19 g, 56%,
Rf ¼ 0.32 in EtOAc/hexane, 1:1) as a white solid, mp 240242 C.
½a22D  5 (c 0.43, CHCl3); lmax 263 nm (ε 25940); 1H NMR (CDCl3):
d 7.95e7.49 (m, 7H, Bz, H-5 and H-6), 6.37 (d, 1H, J10,20 ¼ 9.4 Hz, H-
10), 5.82 (d, 1H, H-20), 5.67 (d, 1H, J40 ,50 ¼ 10.0 Hz, H-40), 4.48e4.40
(m, 1H, H-50), 4.28e4.14 (m, 2H, H-6a0, H-6b0), 2.18, 2.14, 2.11, 2.05
(4s, 12H, 4OAc); Anal. Calcd for C26H26N4O11: C, 54.74; H, 4.59; N,
9.82. Found: C, 54.61; H, 4.65; N, 9.71; ESI-MS (m/z) 571.48
(M þ Hþ).
4.3.8. Synthesis of 1-(30-C-cyano-b-D-glucopyranosyl)cytosine (6d)
Cytosine derivative 6d was synthesized from 5d by the similar
procedure as described for 6a. The residue was purified by flash
chromatography (CH2Cl2/MeOH, 9:1) to afford pure 6d (61 mg, 61%,
Rf ¼ 0.23 in CH2Cl2/MeOH, 7:3) as a white foam. ½a22D  3 (c 0.31,
CD3OD); lmax 269 nm (ε 7569); 1H NMR (CD3OD): d 7.70 (d, 1H,
J5,6 ¼ 7.5 Hz, H-6), 6.12 (d, 1H, J10,20 ¼ 9.0 Hz, H-10), 5.94 (d, 1H, H-5),
4.00e3.69 (m, 5H, H-20, H-40, H-50, H-6a0, H-6b0); 13C NMR (CD3OD):
d 165.72, 156.91, 143.22, 119.16, 94.96, 91.37, 79.96, 72.01, 70.28,
68.16, 61.92; IR (Nujol, cm1): 2235 (CN); Anal. Calcd for
C11H14N4O6: C, 44.30; H, 4.73; N, 18.79. Found: C, 44.48; H, 4.58; N,
18.96; ESI-MS (m/z) 299.23 (M þ Hþ).
4.4. Synthesis of 1,2,4,6-tetra-O-acetyl-3-C-cyano-3-deoxy-D-
allopyranose (10)
4.4.1. Synthesis of 3-C-cyano-3-deoxy-1,2:5,6-di-O-isopropylidene-
a-D-allofuranose (8)
Phenyl chlorothionoformate (1.39 mL, 10.33 mmol) was added
to a solution of 2 (2 g, 7.01 mmol), DMAP (3.03 mmol, 0.37 g), and
Et3N (1.47 mL, 10.69 mmol) in CH3CN (73.68 mL) under nitrogen at
0 C. The mixture was stirred for 1 h and then diluted with AcOEt
(500 mL). The whole was washed with H2O (3  150 ml) and the
separated organic phase was dried over anhydrous sodium sulfate,
filtered and evaporated to dryness. The residue 7was coevaporated
two times with toluene and then was dissolved in toluene
(73.68 mL). Bu3SnH (2.93 mL, 11.06 mmol) was added to the above
solution containing AIBN (1.1 mmol, 182 mg) at 100 C under
nitrogen. After being heated for 45 min, the solvent was removed
under reduced pressure. The residue was purified by flash chro-
matography (EtOAc/hexane, 3:7) to give compound 8 (1.43 g, 76%,
Rf ¼ 0.44 in EtOAc/hexane, 3:7) as a white solid : mp 104106 C.
½a22D þ 16 (c 0.40, CHCl3); 1H NMR (CDCl3): d 5.81 (d, 1H,
J1,2¼ 3.7 Hz, H-1), 4.76 (dd,1H, J2,3¼ 4.8 Hz, H-2), 4.21e3.94 (m, 4H,
H-4, H-5, H-6a, H-6b), 2.88 (dd, 1H, H-3), 1.51 (s, 3H, CH3), 1.42 (s,
3H, CH3), 1.33 (s, 6H, 2 CH3). Anal. Calcd for C13H19NO5: C, 57.98; H,
7.11; N, 5.20. Found: C, 58.12; H, 7.20; N, 5.41; ESI-MS (m/z) 270.27
(M þ Hþ).4.4.2. Synthesis of 3-C-cyano-3-deoxy-a-D-allopyranose (9)
To a solution of 8 (1.43 g, 5.31 mmol) in MeOH (10.9 mL) and
H2O (62.2 mL) was added Amberlite IR 120 (Hþ) resin and the
mixture was refluxed overnight. The reaction mixture was filtered
and evaporated to dryness to give compound 9 (924 mg, 92%,
Rf ¼ 0.17 in EtOAc) as a viscous oil, and it was used without further
purification. ½a22D þ 6 (c 0.45, MeOH); Anal. Calcd for C7H11NO5: C,
44.45; H, 5.86, N, 7.40. Found: C, 44.21; H, 5.92, N, 7.22; ESI-MS: (m/
z) 190.20 (M þ Hþ).
4.4.3. Synthesis of 1,2,4,6-tetra-O-acetyl-3-C-cyano-3-deoxy-D-
allopyranose (10)
Compound 9 (924 mg, 4.89 mmol) was dissolved in a mixture of
pyridine (17.12mL) andAc2O (8.8mL). The reactionwas carried out at
room temperature for 1 h, then was quenched with MeOH at 0 C
and was concentrated in vacuum. The residue was diluted with
EtOAc, washed with saturated sodium bisulfate, sodium bicarbonate
and H2O. The organic extract was dried over anhydrous sodium
sulfate, filtered and evaporated to dryness to give compound 10
(1.56 g, 89%, Rf¼ 0.41 inEtOAc/hexane, 3:7) as a colorless oil. ½a22D  2
(c 0.55, CHCl3); Anal. Calcd for C15H19NO9: C, 50.42; H, 5.36, N, 3.92.
Found: C, 50.54; H, 5.32, N, 3.87; ESI-MS: (m/z) 358.30 (M þ Hþ).
4.5. Synthesis of 30-C-cyano-30-deoxy-b-D-allopyranonucleosides
12aed
4.5.1. Synthesis of 1-(20,40,60-tri-O-acetyl-30-C-cyano-30-deoxy-b-D-
allopyranosyl)5-fluorouracil (11a)
Amixture of 5-fluorouracil (126 mg, 0.97 mmol), HMDS (254 mL,
1.20 mmol) and saccharine (8 mg, 0.045 mmol) in anhydrous
CH3CN (3.5 mL) was refluxed for 30 min under nitrogen. 1,2,4,6-
tetra-O-acetyl-3-C-cyano-3-deoxy D-allopyranose (10) (0.25 g,
0.69 mmol) and Me3SiOSO2CF3 (152 mL, 0.84 mmol) were then
added and the reaction mixture was refluxed for 4 h, cooled,
neutralized with aqueous sodium bicarbonate, and extracted with
CH2Cl2 (200 mL). The organic extract was dried over anhydrous
sodium sulfate, filtered and evaporated to dryness. The residue was
purified by flash chromatography (EtOAc/hexane, 4:6) to give pure
11a (0.19 g, 64%, Rf¼ 0.33 in EtOAc/hexane,1:1) as awhite solid, mp
108110 C. ½a22D  2 (c 0.28, CHCl3); lmax (CHCl3) 263 nm (ε 9073);
1H NMR (CDCl3): d 8.58 (br s,1H, NH), 7.18 (d,1H, J6,F5¼ 5.6 Hz, H-6),
5.93 (d, 1H, J10,20 ¼ 9.4 Hz, H-10), 4.92 (dd, 1H, J20 ,30 ¼ 5.0 Hz, H-20),
5.79 (dd,1H, J30 ,40 ¼ 4.9 Hz, J40 ,50 ¼ 9.7 Hz, H-40), 4.21e4.06 (m, 3H, H-
6a0, H-6b0, H-50), 3.89 (t, 1H, H-30), 2.03, 1.98, 1.96, (3s, 9H, 3OAc);
Anal. Calcd for C17H18FN3O9: C, 47.78; H, 4.25; N, 9.83. Found: C,
47.56; H, 4.31; N, 9.79; ESI-MS (m/z) 428.36 (M þ Hþ).
4.5.2. Synthesis of 1-(30-C-cyano-30-deoxy-b-D-allopyranosyl)5-
fluorouracil (12a)
To a solution of compound 11a (0.19 g, 0.44 mmol) in AcOH-
pyridine (2.2 mL, 1:4 v/v), 85% hydrazine hydrate (0.31 ml,
5.28 mmol) was added at room temperature. After continually
stirring for 16h, acetone (1.1 mL) was added, and stirring for an
additional 30 min. The mixture was evaporated to dryness and the
residue was purified by flash chromatography (CH2Cl2/MeOH, 9:1)
to afford pure 12a (86 mg, 65%, Rf ¼ 0.26 in CH2Cl2/MeOH, 9:1) as
a white foam. ½a22D  8 (c 0.65, CD3OD); lmax 263 nm (ε 8929); 1H
NMR (CD3OD): d 7.80 (d, 1H, J6,F5 ¼ 6.5 Hz, H-6), 6.01 (d, 1H,
J10,20 ¼ 9.2 Hz, H-10), 4.46e4.42 (m, 1H, H-50), 4.23 (dd, 1H,
J30,40 ¼ 5.6 Hz, J40 ,50 ¼12.1 Hz, H-40), 4.05 (dd, 1H, J20,30 ¼ 5.1 Hz, H-20),
3.95e3.84 (m, 2H, H-6a0, H-6b0), 3.75 (t, 1H, H-30); 13C NMR
(CD3OD): d 158.09,150.72,141.39,128.03,118.43, 96.49, 84.37, 67.33,
64.11, 61.09, 29.12; IR (Nujol, cm1): 2250 (CN); Anal. Calcd for
C11H12FN3O6: C, 43.86; H, 4.02; N, 13.95. Found: C, 43.74; H, 3.94; N,
13.82; ESI-MS (m/z) 302.21 (M þ Hþ).
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D-allopyranosyl)uracil (11b)
Uracil derivative 11b was synthesized from 10 by the similar
procedure as described for 11a. It was purified by flash chro-
matography (EtOAc/hexane, 1:1) to give pure 11b (0.18 g, 62%,
Rf ¼ 0.2 in EtOAc/hexane, 1:1) as a white solid, mp 124126 C.
½a22D  2 (c 0.30, CHCl3); lmax 256 nm (ε 13439); 1H NMR
(CDCl3): d 8.27 (br s, 1H, NH), 7.25 (d, 1H, J5,6 ¼ 8.2 Hz, H-6), 6.11
(d, 1H, J10,20 ¼ 9.6 Hz, H-10), 5.80 (d, 1H, H-5), 5.12 (dd, 1H,
J20 ,30 ¼ 5.2 Hz, H-20), 4.96 (dd, 1H, J30 ,40 ¼ 5.0 Hz, J40 ,50 ¼ 9.6 Hz, H-
40), 4.38e4.23 (m, 3H, H-6a0, H-6b0, H-50), 4.06 (t, 1H, H-30), 2.20,
2.15, 2.12 (s, 9H, 3OAc); Anal. Calcd for C17H19N3O9: C, 49.88; H,
4.68; N, 10.27. Found: C, 49.65; H, 4.51; N, 10.36; ESI-MS (m/z)
410.32 (M þ Hþ).
4.5.4. Synthesis of 1-(30-C-cyano-30-deoxy-b-D-allopyranosyl)
uracil (12b)
Uracil derivative 12b was synthesized from 11b by the similar
procedure as described for 12a. The residue was purified by flash
chromatography (CH2Cl2/MeOH, 9:1) to afford pure 12b (91 mg,
75%, Rf ¼ 0.19 in CH2Cl2/MeOH, 9:1) as a white foam. ½a22D  22 (c
0.80, CD3OD); lmax 261 nm (ε 15441); 1H NMR (CD3OD): d 7.61 (d,
1H, J5,6¼ 8.1 Hz, H-6), 5.82 (d,1H, J10,20 ¼ 9.3 Hz, H-10), 5.72 (d,1H, H-
5), 4.46e4.42 (m, 1H, H-50), 4.23 (dd, 1H, J30 ,40 ¼ 5.4 Hz,
J40 ,5¼12.1 Hz, H-40), 4.08 (dd,1H, J20 ,30 ¼ 5.1 Hz, H-20), 3.99e3.84 (m,
2H, H-6a0, H-6b0), 3.76 (t, 1H, H-30); 13C NMR (CD3OD): d 164.01,
150.12,142.27,118.96,102.13, 98.17, 83.96, 66.89, 63.01, 61.20, 30.87;
IR (Nujol, cm1): 2245 (CN); Anal. Calcd for C11H13N3O6: C, 46.65; H,
4.63; N, 14.84. Found: C, 46.96; H, 4.78; N, 14.75; ESI-MS (m/z)
284.22 (M þ Hþ).
4.5.5. Synthesis of 1-(20,40,60-tri-O-acetyl-30-C-cyano-30-deoxy-b-
D-allopyranosyl)thymine (11c)
Thymine derivative 11c was synthesized from 10 by the similar
procedure as described for 11a. It was purified by flash chroma-
tography (EtOAc/hexane,1:1) to give pure 11c (0.19 g, 68%, Rf¼ 0.25
in EtOAc/hexane, 1:1) as a white solid, mp 106108 C. ½a22D  4 (c
0.30, CHCl3); lmax (CHCl3) 261 nm (ε 7290); 1H NMR (CDCl3): d 8.26
(br s, 1H, NH), 7.04 (s, 1H, H-6), 6.1 (d, 1H, J10,20 ¼ 9.7 Hz, H-10), 5.12
(dd, 1H, J20 ,30 ¼ 5.2 Hz, H-20), 5.67 (dd, 1H, J30 ,40 ¼ 4.9 Hz,
J40 ,50 ¼ 9.6 Hz, H-40), 4.38e4.23 (m, 3H, H-6a0, H-6b0, H-50), 4.06 (t,
1H, H-30), 2.19, 2.13, 2.12 (3s, 9H, 3OAc), 1.96 (s, 3H, 5eCH3); Anal.
Calcd for C18H21N3O9: C, 51.06; H, 5.00; N, 9.93. Found: C, 50.87; H,
4.96; N, 9.87; ESI-MS (m/z) 424.39 (M þ Hþ).
4.5.6. Synthesis of 1-(30-C-cyano-30-deoxy-b-D-allopyranosyl)
thymine (12c)
Thymine derivative 12cwas synthesized from 11c by the similar
procedure as described for 12a. The residue was purified by flash
chromatography (CH2Cl2/MeOH, 9:1) to afford pure 12c (99 mg,
71%, Rf ¼ 0.20 in CH2Cl2/MeOH, 9:1) as a white foam. ½a22D  16 (c
0.50, CD3OD); lmax 262 nm (ε 14609); 1H NMR (CD3OD): d 7.40 (s,
1H, H-6), 5.77 (d, 1H, J10,20 ¼ 9.4 Hz, H-10), 4.46e4.42 (m, 1H, H-50),
4.24 (dd, 1H, J30 ,40 ¼ 5.6 Hz, J40 ,5 ¼ 12.0 Hz, H-40), 4.11 (dd, 1H,
J20 ,30 ¼ 5.1 Hz, H-20), 3.99e3.84 (m, 2H, H-6a0, H-6b), 3.70 (t, 1H, H-
30), 1.91 (s, 3H, 5eCH3); 13C NMR (CD3OD): d 163.67, 150.19, 136.85,
119.01, 110.63, 97.67, 84.15, 67.29, 64.55, 61.30, 28.02, 12.68; IR
(Nujol, cm1): 2240 (CN); Anal. Calcd for C12H15N3O6: C, 48.48; H,
5.09; N, 14.14. Found: C, 48.82; H, 5.12; N, 14.09; ESI-MS (m/z)
298.27 (M þ Hþ).
4.5.7. Synthesis of 1-(20,40,60-tri-O-acetyl-30-C-cyano-30-deoxy-b-
D-allopyranosyl)N4-benzoylcytosine (11d)
N4-benzoylcytosine derivative 11d was synthesized from 10 by
the similar procedure as described for 11a. It was purified by flashchromatography (EtOAc/hexane, 1:1) to give pure 11d (0.21 g, 59%,
Rf ¼ 0.23 in EtOAc/hexane, 1:1) as a white solid, mp 203205 C.
[a]D22 þ 2 (c 0.28, CHCl3); lmax 264 nm (ε 14496); 1H NMR (CDCl3):
d 7.94e7.51 (m, 7H, Bz, H5 and H-6), 6.40 (d, 1H, J10,20 ¼ 9.6 Hz, H-10),
5.17 (dd, 1H, J20 ,30 ¼ 5.2 Hz, H-20), 5.01 (dd, 1H, J30 ,40 ¼ 5.0 Hz,
J40 ,50 ¼ 9.9 Hz, H-40), 4.41e4.24 (m, 3H, H-6a0, H-6b0, H-50), 4.06 (t,
1H, H-30), 2.19, 2.14, 2.11 (3s, 9H, 3OAc); Anal. Calcd for C24H24N4O9:
C, 56.25; H, 4.72; N,10.93. Found: C, 56.64; H, 4.69; N,10.68; ESI-MS
(m/z) 513.48 (M þ Hþ).
4.5.8. Synthesis of 1-(30-C-cyano-30-deoxy-b-D-allopyranosyl)
cytosine (12d)
Cytosine derivative 12d was synthesized from 11d by the
similar procedure as described for 12a. The residue was purified
by flash chromatography (CH2Cl2/MeOH, 9:1) to afford pure 12d
(33 mg, 55%, Rf ¼ 0.25 in CH2Cl2/MeOH, 7:3) as an orange foam.
½a22D  6 (c 0.50, CD3OD); lmax 266 nm (ε 12306); 1H NMR
(CD3OD): d 7.68 (d, 1H, J5,6 ¼ 7.5 Hz, H-6), 5.97 (d, 1H,
J10,20 ¼ 9.0 Hz, H-10), 5.97 (d, 1H, H-5), 4.13e3.74 (m, 6H, H-20, H-
30, H-40, H-50, H-6a0, H-6b0); 13C NMR (CD3OD): d 165.79, 155.73,
143.46, 118.86, 96.37, 94.96, 84.01, 67.38, 63.71, 61.32, 27.83; IR
(Nujol, cm1): 2235 (CN); Anal. Calcd for C11H14N4O5: C, 46.81; H,
5.00; N, 19.85. Found: C, 46.56; H, 4.78; N, 19.41; ESI-MS (m/z)
283.28 (M þ Hþ).
4.5.9. Antiviral and cytostatic assays
The antiviral assays [except anti-human immunodeficiency
virus (HIV) assays] were based on inhibition of virus-induced
cytopathicity in HEL [herpes simplex virus type 1 (HSV-1), HSV-
2 (G), vaccinia virus, and vesicular stomatitis virus], Vero (para-
influenza-3, reovirus-1, Coxsackie B4, and Punta Toro virus), HeLa
(vesicular stomatitis virus, Coxsackie virus B4, and respiratory
syncytial virus), MDCK (influenza A (H1N1; H3N2) and B virus)
and CrFK (feline corona virus (FIPV) and feline herpes virus) cell
cultures. Confluent cell cultures in microtiter 96-well plates were
inoculated with 100 cell culture inhibitory dose-50 (CCID50) of
virus (1 CCID50 being the virus dose to infect 50% of the cell
cultures) in the presence of varying concentrations (5,000, 1,000,
200 . nM) of the test compounds. Viral cytopathicity was
recorded as soon as it reached completion in the control virus-
infected cell cultures that were not treated with the test
compounds.
The anti-HIV activity and anti-proliferative activity were
evaluated against HIV-1 strain IIIB and HIV-2 strain ROD in
human T-lymphocyte CEM cell cultures. Briefly, virus stocks were
titrated in CEM cells and expressed as the 50% cell culture
infective dose (CCID50). CEM cells were suspended in culture
medium at w3  105 cells/ml and infected with HIV at w100
CCID50. Immediately after viral exposure, 100 ml of the cell
suspension was placed in each well of a flat-bottomed microtiter
tray containing various concentrations of the test compounds.
After a 4-day incubation period at 37 C, the giant cell formation
was microscopically determined. Compounds were tested in
parallel for cytostatic effects in uninfected CEM cells.
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